PDF herunterladen
Pharmacopsychiatry 2010; 43(6): 225-232
DOI: 10.1055/s-0030-1254153
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Characteristics and Clinical Changes during Hospitalization in Bipolar and Psychotic Disorder Patients with versus without Substance-Use Disorders

A. Vincenti1 , 2 , 3 , A. Ventriglio2 , 3 , 4 , R. J. Baldessarini2 , 5 , A. Talamo1 , 2 , 5 , G. Fitzmaurice5 , F. Centorrino2 , 3 , 5
  • 1Department of Neurosciences, Mental Health, and Sensory Functions (NESMOS), Second Medical School, Sapienza University of Rome, and Unit of Psychiatry, Sant’ Andrea Hospital, Rome, Italy
  • 2International Consortium for Psychotic and Bipolar Disorder Research, McLean Division of Massachusetts General Hospital, Belmont, MA, USA
  • 3Psychopharmacology Research Department, McLean Hospital, Belmont, MA, USA
  • 4Department of Psychiatry, University of Foggia, Foggia, Italy
  • 5Department of Psychiatry, Harvard Medical School, Boston, MA, USA
Weitere Informationen

Publikationsverlauf

received 09.11.2009 revised 21.04.2010

accepted 28.04.2010

Publikationsdatum:
22. Juli 2010 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Background: Co-morbid substance-use disorders (SUDs) are prevalent among patients with severe psychiatric disorders, but the characteristics of such patients remain incompletely defined, and their current treatments and responses, poorly documented.

Methods: We evaluated the records of 481 consecutive inpatients diagnosed with DSM-IV bipolar or schizoaffective disorders, or schizophrenia, admitted to McLean Hospital in 2004 or 2009. Demographic and clinical characteristics, and treatments, were extracted from hospital and pharmacy records for bivariate and multivariate analyses.

Results: SUD prevalence increased 1.84-times from 2004 (31.3%) to 2009 (57.6%). Patients with (n=204) versus without co-morbid SUDs (n=277) were similar in many respects, but in multivariate modeling, the following factors were more likely with SUD, in rank-order: co-morbid anxiety disorders > men more than women > greater prevalence in 2009 vs. 2004 > younger age > greater doses of mood-stabilizers > shorter hospitalization.

Conclusions: Hospitalized patients with severe primary psychiatric disorders, and comorbid SUD were more likely to be young and have anxiety disorders, to receive more combinations and higher doses of mood-stabilizers, and show more improvement in impulsivity and hostility, but otherwise differed little in treatment-responses. Prevalence of SUD rose substantially in the past five years, with increased but largely unproved use of mood-stabilizers.

References

  • 1 Addington J, Duchak V. Reasons for substance use in schizophrenia.  Acta Psychiatr Scand. 1997;  96 329-333
    CrossrefPubMedGoogle Scholar
  • 2 Baethge C, Baldessarini RJ, Khalsa HM. et al . Substance abuse in first-episode bipolar I disorder: indications for early intervention.  Am J Psychiatry. 2005;  162 1008-1010
    CrossrefPubMedGoogle Scholar
  • 3 Baldessarini RJ, Tarazi FI. Antipsychotic and antimanic agents.. Chapt 18 in Hardman JG, Limbird LE, Gilman AG (eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics, Eleventh Edition. New York: McGraw-Hill; 2005: 461-500
    Google Scholar
  • 4 Baldessarini RJ, Tondo L, Davis P. et al . Decreased risk of suicides and attempts during long-term lithium treatment: meta-analytic review.  Bipolar Disord. 2006;  8 625-639
    Google Scholar
  • 5 Bizzarri JV, Rucci P, Sbrana A. et al . Substance use in severe mental illness: self-medication and vulnerability factors.  Psychiatry Res. 2009;  165 88-95
    CrossrefPubMedGoogle Scholar
  • 6 Bradizza CM, Stasiewicz PR. Qualitative analysis of high-risk drug and alcohol use situations among severely mentally ill substance abusers.  Addict Behav. 2003;  28 157-169
    CrossrefPubMedGoogle Scholar
  • 7 Brady KT, Myrick H, Sonne S. Co-occurring addictive and affective disorders.. In Principles of Addiction Medicine, third edition. Graham AW, Schultz TK, Mayo-Smith MF, Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB (eds) Chevy Chase, MD: American Society of Addiction Medicine (ASAM); 2003: 1277-1286
    Google Scholar
  • 8 Brown ES, Perantie DC, Dhanani N. et al . Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study.  J Affect Disord. 2006;  93 219-222
    CrossrefPubMedGoogle Scholar
  • 9 Buckley PF. New antipsychotic agents: emerging clinic profiles.  J. Clin. Psychiatry. 1999;  60 12-17
    PubMedGoogle Scholar
  • 10 Cassidy F, Ahearn EP, Carroll BJ. Substance abuse in bipolar disorder.  Bipolar Disord. 2001;  3 181-188
    CrossrefPubMedGoogle Scholar
  • 11 Centorrino F, Sani G, Fogarty KV. et al . Combinations of mood-stabilizers with antipsychotics as treatment strategies in hospitalized psychiatric patients.  Clin Neuropsychiatry. 2006;  3 322-326
    PubMedGoogle Scholar
  • 12 Dixon L, Haas G, Weiden PJ. et al . Drug abuse in schizophrenic patients: clinical correlates and reasons for use.  Am J Psychiatry. 1991;  48 224-230
    PubMedGoogle Scholar
  • 13 Drake RE, Xie H, McHugo GJ. et al . Effects of clozapine on alcohol and drug use disorders among patients with schizophrenia.  Schizophrenia Bull. 2000;  26 440-449
    PubMedGoogle Scholar
  • 14 Erkiran M, Ozonalan H, Euren C. et al . Substance abuse amplifies the risk for violence in schizophrenia spectrum disorder.  Addict Behav. 2006;  31 1797-1805
    CrossrefPubMedGoogle Scholar
  • 15 Geller B, Cooper TB, Sun K. et al . Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency.  J Am Acad Child Adolesc Psychiatry. 1998;  37 171-178
    CrossrefPubMedGoogle Scholar
  • 16 Goldberg JF, Garno JL, Kocsis JH. et al . Correlates of suicidal ideation in disphoric mania.  J Affect Disord. 1999a;  56 75-81
    CrossrefPubMedGoogle Scholar
  • 17 Goldberg JF, Garno JL, Leon AC. et al . History of substance abuse complicates remission from acute mania in bipolar disorder.  J Clin Psychiatry. 1999;  60 733-740
    CrossrefPubMedGoogle Scholar
  • 18 Goldstein BI, Diamantouros A, Schaffer A. et al . Pharmacotherapy of alcoholism in patients with co-morbid psychiatric disorders.  Drugs. 2006;  66 1229-1237
    CrossrefPubMedGoogle Scholar
  • 19 Green AI. Pharmacotherapy for schizophrenia and co-occurring substance use disorders.  Neurotox Res. 2007;  11 33-40
    CrossrefPubMedGoogle Scholar
  • 20 Helzer JE, Pryzbeck TR. The co-occurrence of alcoholism with other psychiatric disorders in the general population and its impact on treatment.  J Stud Alcohol. 1998;  49 219-224
    PubMedGoogle Scholar
  • 21 Hendrickson EL. Designing, Implementing, and Managing Treatment Services for Individuals with Co-occurring Mental Health and Substance Use Disorders: Blueprints for Action.. Binghamton, NY: Haworth; 2006: 5-40
    Google Scholar
  • 22 Hser H, Grella C, Evans E. et al . Utilization and outcomes of mental health services among patients in drug treatment.  J Addict Disord. 2006;  25 73-85
    PubMedGoogle Scholar
  • 23 Kessler RC, Nelson CB, McGonagle KA. et al . The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization.  Am J Orthopsychiatry. 1996;  66 17-31
    CrossrefPubMedGoogle Scholar
  • 24 Kushner MG, Abrams K, Borchardt C. The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings.  Clin Psychol Rev. 2000;  29 149-171
    PubMedGoogle Scholar
  • 25 Mueser KT, Drake RE, Wallach MA. Dual diagnosis: review of etiological theories.  Addict Behav. 1998;  23 717-734
    Google Scholar
  • 26 Regier DA, Farmer MD, Rae DS. et al . Co-morbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study.  JAMA. 1990;  264 2511-2518
    Google Scholar
  • 27 Rubio G, López-Muñoz F, Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence.  Bipolar Disord. 2006;  8 289-293
    CrossrefPubMedGoogle Scholar
  • 28 Salloum IM, Cornelius JR, Daley DC. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: double-blind placebo-controlled study.  Arch Gen Psychiatry. 2005;  62 37-45
    CrossrefPubMedGoogle Scholar
  • 29 Salloum IM, Cornelius JR, Mezzich JE. et al . Impact of concurrent alcohol mis use on symptom presenation of acute mania at initial evaluation.  Bipolar Disord. 2002;  4 418-421
    CrossrefPubMedGoogle Scholar
  • 30 Schofield D, Tennant C, Nash L. et al . Reasons for cannabis use in psychosis.  Austral NZ J Psychiatry. 2006;  40 570-574
    PubMedGoogle Scholar
  • 31 Strakowski SM, Keck Jr PE, McElroy SL. et al . Twelve-month outcome after a first hospitalization for affective psychosis.  Arch Gen Psychiatry. 1998;  55 49-55
    CrossrefPubMedGoogle Scholar
  • 32 Swartz MS, Wagner HR, Swanson JW. et al . Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study.  J Nerv Ment Dis. 2006;  194 164-172
    PubMedGoogle Scholar
  • 33 Tenhula WN, Bennett ME, Strong Kinnaman JE. Behavioral treatment of substance abuse in schizophrenia.  J Clin Psychol. 2009;  65 831-841
    CrossrefPubMedGoogle Scholar
  • 34 Tohen M, Waternaux CM, Tsuang MT. Outcome in mania: four year prospective follow up of 75 patients utilizing survival analysis.  Arch Gen Psychiatry. 1990;  47 1106-1111
    PubMedGoogle Scholar
  • 35 Ventriglio A, Vincenti A, Centorrino F. et al . Use of mood-stabilizers for hospitalized adult psychotic and bipolar disorder patients.  J Int Clin Psychopharmacol. 2010;  in press
    PubMedGoogle Scholar
  • 36 Verheul R. Co-morbidity of personality disorders in individuals with substance use disorders.  Eur Psychiatry. 2001;  16 274-282
    CrossrefPubMedGoogle Scholar
  • 37 Weiss RD, Griffin ML, Jaffee WB. et al . A “community-friendly” version of integrated group therapy for patients with bipolar disorder and substance dependence: randomized controlled trial.  Drug Alcohol Depend. 2009;  104 212-219
    CrossrefPubMedGoogle Scholar
  • 38 Weiss RD, Ostacher MJ, Otto MW. et al . Does recovery from substance use disorder matter in patients with bipolar disorder?.  J Clin Psychiatry. 2005;  66 730-735
    CrossrefPubMedGoogle Scholar
  • 39 Winokur G, Coryell W, Akiskal HS. et al . Alcoholism in manic-depressive (bipolar) illness: familial illness, course of illness, and primary-secondary distinction.  Am J Psychiatry. 1995;  152 365-372
    PubMedGoogle Scholar
  • 40 Ziedonis DM, Smelson D, Rosenthal RN. Improving care of individuals with schizophrenia and substance use disorders: consensus recommendations.  J Psychiatr Pract. 2005;  11 315-339
    CrossrefPubMedGoogle Scholar

Correspondence

Dr. F. Centorrino

North Belknap 3

McLean Hospital

115 Mill Street

Belmont

MA 02478-9106

USA

Telefon: +1/617/855 2136

Fax: +1/617/855 3826

eMail: fcentorrino@mclean.harvard.edu

      >